

# Masataka Tsuge

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1240756/publications.pdf>

Version: 2024-02-01

188  
papers

4,883  
citations

87888

38  
h-index

138484

58  
g-index

194  
all docs

194  
docs citations

194  
times ranked

6306  
citing authors

#	ARTICLE	IF	CITATIONS
1	Enhanced SMYD3 expression is essential for the growth of breast cancer cells. <i>Cancer Science</i> , 2006, 97, 113-118.	3.9	246
2	Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. <i>Hepatology</i> , 2005, 42, 1046-1054.	7.3	138
3	G to A hypermutation of hepatitis B virus. <i>Hepatology</i> , 2005, 41, 626-633.	7.3	136
4	Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. <i>Journal of Hepatology</i> , 2010, 53, 439-443.	3.7	128
5	A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers. <i>Nature Genetics</i> , 2005, 37, 1104-1107.	21.4	112
6	Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. <i>Hepatology Research</i> , 2018, 48, 51-58.	3.4	110
7	HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice. <i>Journal of General Virology</i> , 2010, 91, 1854-1864.	2.9	90
8	IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. <i>Journal of Hepatology</i> , 2011, 54, 1094-1101.	3.7	84
9	Serum interleukin-6 associated with hepatocellular carcinoma risk: A nested case-control study. <i>International Journal of Cancer</i> , 2014, 134, 154-163.	5.1	82
10	A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections. <i>Biochemical and Biophysical Research Communications</i> , 2013, 441, 230-235.	2.1	80
11	Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. <i>Journal of Medical Virology</i> , 2015, 87, 1913-1920.	5.0	73
12	Involvement of <i>Porphyromonas gingivalis</i> in the progression of non-alcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2018, 53, 269-280.	5.1	73
13	Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. <i>Journal of Hepatology</i> , 2011, 54, 408-414.	3.7	72
14	Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. <i>Hepatology</i> , 2011, 54, 781-788.	7.3	70
15	Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. <i>Journal of Gastroenterology</i> , 2013, 48, 1188-1204.	5.1	70
16	Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 516-534.	4.5	67
17	Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2013, 85, 789-798.	5.0	66
18	Dual effect of APOBEC3G on Hepatitis B virus. <i>Journal of General Virology</i> , 2007, 88, 432-440.	2.9	65

#	ARTICLE	IF	CITATIONS
19	Emergence of a Novel Lamivudine-Resistant Hepatitis B Virus Variant with a Substitution Outside the YMDD Motif. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3867-3874.	3.2	63
20	On-Treatment Low Serum HBV RNA Level Predicts Initial Virological Response in Chronic Hepatitis B Patients Receiving Nucleoside Analogue Therapy. <i>Antiviral Therapy</i> , 2015, 20, 369-375.	1.0	61
21	Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. <i>Hepatology Research</i> , 2016, 46, 758-764.	3.4	60
22	Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. <i>Hepatology</i> , 2007, 45, 1179-1186.	7.3	57
23	Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2012, 42, 139-149.	3.4	57
24	Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. <i>Hepatology Research</i> , 2013, 43, 1182-1189.	3.4	55
25	Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon. <i>FEBS Letters</i> , 2007, 581, 1983-1987.	2.8	52
26	Differences in serum microRNA profiles in hepatitis B and C virus infection. <i>Journal of Infection</i> , 2015, 70, 273-287.	3.3	52
27	Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1009-1015.	2.8	52
28	Hepatitis B Virus-Specific miRNAs and Argonaute2 Play a Role in the Viral Life Cycle. <i>PLoS ONE</i> , 2012, 7, e47490.	2.5	51
29	Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. <i>Journal of Hepatology</i> , 2011, 54, 872-878.	3.7	45
30	Animal model for study of human hepatitis viruses. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 13-18.	2.8	45
31	Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. <i>Journal of Medical Virology</i> , 2011, 83, 1048-1057.	5.0	45
32	The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. <i>PLoS ONE</i> , 2017, 12, e0182710.	2.5	44
33	Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse. <i>Hepatology</i> , 2012, 56, 555-566.	7.3	43
34	Levodopa Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis. <i>Hepatology Communications</i> , 2019, 3, 348-355.	4.3	43
35	A Polymorphism in MAPKAPK3 Affects Response to Interferon Therapy for Chronic Hepatitis C. <i>Gastroenterology</i> , 2009, 136, 1796-1805.e6.	1.3	42
36	Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 177-184.	1.0	42

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. <i>Hepatology Research</i> , 2015, 45, 656-662.	3.4	42
38	Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. <i>Hepatology Research</i> , 2018, 48, 814-820.	3.4	41
39	Role of conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, 607-617.	3.4	40
40	Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. <i>Journal of Gastroenterology</i> , 2019, 54, 291-296.	5.1	39
41	Preoperative Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Prediction of Microvascular Invasion in Small Hepatocellular Carcinoma. <i>Journal of Computer Assisted Tomography</i> , 2016, 40, 524-530.	0.9	38
42	Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma. <i>Oncology</i> , 2021, 99, 507-517.	1.9	38
43	Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00179.	2.5	37
44	Successful treatment of an entecavir-resistant hepatitis B virus variant. <i>Journal of Medical Virology</i> , 2007, 79, 1811-1817.	5.0	35
45	HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study. <i>PLoS ONE</i> , 2013, 8, e84226.	2.5	35
46	Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice. <i>Journal of General Virology</i> , 2008, 89, 2108-2113.	2.9	34
47	Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. <i>Oncology</i> , 2018, 94, 215-222.	1.9	33
48	G to A hypermutation of TT virus. <i>Virus Research</i> , 2010, 149, 211-216.	2.2	32
49	Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor. <i>Journal of General Virology</i> , 2010, 91, 1668-1677.	2.9	31
50	Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. <i>Hepatology</i> , 2011, 54, 764-771.	7.3	31
51	Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. <i>Journal of Hepatology</i> , 2009, 51, 1046-1054.	3.7	30
52	Impact of radiation and hepatitis virus infection on risk of hepatocellular carcinoma. <i>Hepatology</i> , 2011, 53, 1237-1245.	7.3	30
53	Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long-term outcomes in 14 patients. <i>Hepatology Research</i> , 2014, 44, 740-749.	3.4	29
54	Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A. <i>Journal of Hepatology</i> , 2015, 63, 554-563.	3.7	29

#	ARTICLE	IF	CITATIONS
55	Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. <i>Journal of Medical Virology</i> , 2011, 83, 1597-1607.	5.0	28
56	Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1780-1786.	2.8	28
57	Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury. <i>Journal of Gastroenterology</i> , 2017, 52, 1252-1257.	5.1	27
58	Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. <i>Liver Cancer</i> , 2020, 9, 148-155.	7.7	27
59	Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab. <i>Hepatology Research</i> , 2020, 50, 885-888.	3.4	27
60	Effects of structural variations of <i>APOBEC3A</i> and <i>APOBEC3B</i> genes in chronic hepatitis B virus infection. <i>Hepatology Research</i> , 2009, 39, 1159-1168.	3.4	26
61	Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. <i>Gut</i> , 2013, 62, 1055-1061.	12.1	26
62	The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy. <i>Journal of Medical Virology</i> , 2019, 91, 650-658.	5.0	26
63	Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. <i>Oncology</i> , 2020, 98, 787-797.	1.9	26
64	Effects of Hepatitis B Virus Infection on the Interferon Response in Immunodeficient Human Hepatocyte Chimeric Mice. <i>Journal of Infectious Diseases</i> , 2011, 204, 224-228.	4.0	23
65	Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice. <i>Journal of Virology</i> , 2015, 89, 10087-10096.	3.4	23
66	Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 215.	8.6	23
67	Factors associated with the effect of interferon-free sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2015, 45, 1195-1202.	3.4	22
68	Hypermutation in Hepatitis B Virus (HBV) and Clinical Course of Patients with Chronic HBV Infection. <i>Journal of Infectious Diseases</i> , 2009, 199, 1599-1607.	4.0	21
69	Noninvasive assessment of liver steatosis in nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2014, 44, E420-7.	3.4	21
70	Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2014, 49, 1548-1556.	5.1	21
71	Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report. <i>Hepatology Research</i> , 2016, 46, 944-948.	3.4	21
72	Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection. <i>Journal of Gastroenterology</i> , 2016, 51, 1073-1080.	5.1	21

#	ARTICLE	IF	CITATIONS
73	Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring. PLoS ONE, 2018, 13, e0195028.	2.5	21
74	The effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 619-627.	2.8	20
75	Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes. Virology, 2018, 525, 48-61.	2.4	20
76	Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. Liver Cancer, 2021, 10, 151-160.	7.7	20
77	IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. Journal of Gastroenterology, 2012, 47, 834-844.	5.1	19
78	Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis. Journal of Gastroenterology, 2013, 48, 847-855.	5.1	19
79	Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1035-1042.	2.8	19
80	Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma. European Radiology, 2015, 25, 3272-3281.	4.5	19
81	Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatology Research, 2016, 46, E146-53.	3.4	19
82	ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. Journal of Gastroenterology, 2017, 52, 746-753.	5.1	19
83	Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 726-732.	2.8	18
84	Regulation of the Hepatitis B virus replication and gene expression by the multi-functional protein TARDBP. Scientific Reports, 2019, 9, 8462.	3.3	18
85	Non-invasive liver fibrosis score calculated by combination of virtual touch tissue quantification and serum liver functional tests in chronic hepatitis C patients. Hepatology Research, 2014, 44, 280-287.	3.4	17
86	Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones. Journal of Infection, 2016, 72, 91-102.	3.3	17
87	Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	17
88	Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy. Journal of Gastroenterology, 2018, 53, 107-118.	5.1	17
89	Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. BMC Cancer, 2018, 18, 633.	2.6	17
90	Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. BMC Gastroenterology, 2021, 21, 306.	2.0	17

#	ARTICLE	IF	CITATIONS
91	Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology. <i>Journal of General Virology</i> , 2017, 98, 1040-1047.	2.9	17
92	Hepatitis C Virus Infection Suppresses the Interferon Response in the Liver of the Human Hepatocyte Chimeric Mouse. <i>PLoS ONE</i> , 2011, 6, e23856.	2.5	16
93	A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing. <i>American Journal of Gastroenterology</i> , 2013, 108, 1464-1472.	0.4	16
94	Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2105-2112.	3.2	16
95	Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation. <i>Hepatology Research</i> , 2015, 45, 1047-1054.	3.4	16
96	Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Comparison with primary cases. <i>European Journal of Radiology</i> , 2015, 84, 1540-1545.	2.6	16
97	Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2017, 52, 504-511.	5.1	16
98	Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 193-204.	3.4	16
99	Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis. <i>Journal of Gastroenterology</i> , 2020, 55, 217-226.	5.1	16
100	Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 867-872.	0.8	16
101	Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus. <i>PLoS ONE</i> , 2017, 12, e0172412.	2.5	16
102	Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection. <i>Hepatology Research</i> , 2017, 47, 767-772.	3.4	15
103	Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. <i>Journal of Gastroenterology</i> , 2018, 53, 247-257.	5.1	15
104	Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice. <i>Biochemical and Biophysical Research Communications</i> , 2018, 500, 152-157.	2.1	15
105	Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis. <i>Hepatology Research</i> , 2020, 50, 1234-1243.	3.4	15
106	Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	14
107	Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis. <i>BMC Gastroenterology</i> , 2019, 19, 169.	2.0	14
108	Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection. <i>European Journal of Radiology</i> , 2020, 124, 108828.	2.6	14



#	ARTICLE	IF	CITATIONS
109	A case with life-threatening secondary sclerosing cholangitis caused by nivolumab. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 283-287.	0.8	14
110	Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice. <i>Journal of Virology</i> , 2021, 95, e0049220.	3.4	14
111	Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C. <i>Hepatology Research</i> , 2014, 44, E447-54.	3.4	13
112	Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 1118-1130.	3.4	13
113	Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy. <i>Scientific Reports</i> , 2019, 9, 12101.	3.3	13
114	Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. <i>Hepatology Research</i> , 2020, 50, 1222-1233.	3.4	13
115	Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2010, 15, 1087-1097.	1.0	12
116	Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1467-1472.	2.8	12
117	Late-onset ornithine transcarbamylase deficiency associated with hyperammonemia. <i>Clinical Journal of Gastroenterology</i> , 2017, 10, 383-387.	0.8	12
118	The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients. <i>Journal of Gastroenterology</i> , 2017, 52, 366-375.	5.1	12
119	Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C. <i>Journal of Medical Virology</i> , 2018, 90, 1834-1840.	5.0	12
120	Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: Analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 1488-1496.	1.5	11
121	Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report. <i>Hepatology Research</i> , 2016, 46, 707-712.	3.4	11
122	Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing. <i>Journal of Infectious Diseases</i> , 2016, 214, 1687-1694.	4.0	11
123	Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib. <i>Oncology</i> , 2017, 92, 335-346.	1.9	11
124	Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients. <i>Journal of Medical Virology</i> , 2017, 89, 1963-1972.	5.0	11
125	Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 645-650.	2.8	11
126	Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092205.	3.2	11



#	ARTICLE	IF	CITATIONS
127	MafF Is an Antiviral Host Factor That Suppresses Transcription from Hepatitis B Virus Core Promoter. <i>Journal of Virology</i> , 2021, 95, e0076721.	3.4	11
128	Ecabet sodium induces neuronal nitric oxide synthase-derived nitric oxide synthesis and gastric adaptive relaxation in the human stomach. <i>Journal of Gastroenterology</i> , 2009, 44, 1118-1124.	5.1	10
129	Prediction of response to peginterferon- $\alpha$ 2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. <i>Journal of Medical Virology</i> , 2011, 83, 981-988.	5.0	10
130	Combination Therapies with Daclatasvir and Asunaprevir on NS3-D168 Mutated HCV in Human Hepatocyte Chimeric Mice. <i>Antiviral Therapy</i> , 2016, 21, 307-315.	1.0	10
131	The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study. <i>Journal of Gastroenterology</i> , 2017, 52, 113-122.	5.1	10
132	Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1412-1419.	2.8	10
133	Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration. <i>Journal of Infectious Diseases</i> , 2020, 222, 1165-1169.	4.0	10
134	Signal Activation of Hepatitis B Virus-Related Hepatocarcinogenesis by Up-regulation of SUV39h1. <i>Journal of Infectious Diseases</i> , 2020, 222, 2061-2070.	4.0	10
135	ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo. <i>Journal of Hepatology</i> , 2011, 55, 11-18.	3.7	9
136	Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation. <i>Hepatology Research</i> , 2014, 44, 1259-1264.	3.4	9
137	Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction. <i>Journal of Medical Virology</i> , 2017, 89, 665-671.	5.0	9
138	Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study. <i>Journal of Gastroenterology</i> , 2018, 53, 548-556.	5.1	9
139	Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: A pilot study. <i>Antiviral Therapy</i> , 2018, 23, 639-646.	1.0	9
140	PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication. <i>Journal of Gastroenterology</i> , 2020, 55, 1162-1170.	5.1	9
141	Elimination of HCV via a non-ISC-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice. <i>Virus Research</i> , 2016, 213, 62-68.	2.2	8
142	The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients. <i>Antiviral Therapy</i> , 2017, 23, 239-248.	1.0	8
143	Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection. <i>BMC Gastroenterology</i> , 2020, 20, 314.	2.0	8
144	Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2020, 55, 977-989.	5.1	8

#	ARTICLE	IF	CITATIONS
145	Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors. <i>Oncology</i> , 2020, 98, 727-733.	1.9	8
146	Clinical Usefulness of Serum Autotaxin for Early Prediction of Relapse in Male Patients with Type 1 Autoimmune Pancreatitis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1268-1275.	2.3	8
147	Effects of <i>ITPA</i> polymorphism on decrease of hemoglobin during simeprevir, peginterferon, and ribavirin combination treatment for chronic hepatitis C. <i>Hepatology Research</i> , 2016, 46, 1256-1263.	3.4	7
148	Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure. <i>Journal of General Virology</i> , 2018, 99, 1058-1065.	2.9	7
149	<i>CTL</i> -associated and <i>NK</i> cell-associated immune responses induce different <i>HBV</i> DNA reduction patterns in chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1555-1564.	2.0	6
150	Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 341-346.	0.8	6
151	Comparison of intracellular responses between <i>HBV</i> genotype A and C infection in human hepatocyte chimeric mice. <i>Journal of Gastroenterology</i> , 2019, 54, 650-659.	5.1	6
152	Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice. <i>Journal of General Virology</i> , 2019, 100, 1123-1131.	2.9	6
153	Availability of monitoring serum <i>HBV</i> DNA plus RNA during nucleot(s)ide analogue therapy. <i>Journal of Gastroenterology</i> , 2013, 48, 779-780.	5.1	5
154	Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy. <i>Journal of Medical Virology</i> , 2020, 92, 210-218.	5.0	5
155	Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1685-1693.	2.8	5
156	Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy. <i>Oncology</i> , 2021, 99, 327-335.	1.9	5
157	<i>In vitro</i> analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism. <i>Molecular Medicine Reports</i> , 2020, 23, .	2.4	5
158	Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 592-599.	2.8	5
159	Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B. <i>PLoS ONE</i> , 2022, 17, e0263844.	2.5	5
160	The kinesin KIF4 mediates <i>HBV</i> / <i>HDV</i> entry through the regulation of surface NTCP localization and can be targeted by RXR agonists in vitro. <i>PLoS Pathogens</i> , 2022, 18, e1009983.	4.7	5
161	Importance of Serum Concentration of Adefovir for Lamivudine-Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3205-3211.	3.2	4
162	<i>IFNL4</i> polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C. <i>Hepatology Research</i> , 2017, 47, E5-E13.	3.4	4

#	ARTICLE	IF	CITATIONS
163	The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2017, 52, 253-262.	5.1	4
164	Early experience of seven hepatocellular carcinoma cases treated with regorafenib. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 2217-2223.	0.5	4
165	The association between hepatocarcinogenesis and intracellular alterations due to hepatitis B virus infection. <i>Liver International</i> , 2021, 41, 2836-2848.	3.9	4
166	Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis. <i>Hepatology Research</i> , 2018, 48, 264-274.	3.4	3
167	Successful retreatment with 12Âweeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8Âweeks of prior glecaprevir and pibrentasvir therapy. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 267-270.	0.8	3
168	Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection. <i>Internal Medicine</i> , 2020, 59, 941-944.	0.7	3
169	A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 839-843.	0.8	3
170	Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients. <i>Journal of Infection</i> , 2022, 84, 391-399.	3.3	3
171	The first Japanese case of COACH syndrome. <i>Hepatology Research</i> , 2009, 39, 318-323.	3.4	2
172	Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region. <i>Hepatology Research</i> , 2011, 41, 1126-1131.	3.4	2
173	Achievement of Sustained Viral Response after Switching Treatment from Pegylated Interferon a-2b to a-2a and Ribavirin in Patients with Recurrence of Hepatitis C Virus Genotype 1 Infection after Liver Transplantation: A Case Report. <i>Intervirolgy</i> , 2012, 55, 122-126.	2.8	2
174	Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation. <i>Clinical Journal of Gastroenterology</i> , 2017, 10, 179-184.	0.8	2
175	Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures. <i>Internal Medicine</i> , 2021, 60, 829-837.	0.7	2
176	Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1304-1311.	2.0	2
177	A case of fulminant hepatic failure caused by hepatitis E virus. <i>Clinical Journal of Gastroenterology</i> , 2008, 1, 69-74.	0.8	1
178	Identification of novel hepatitis C virus deletion mutants in chronic hepatitis C patients. <i>Antiviral Therapy</i> , 2012, 17, 1551-1561.	1.0	1
179	Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection. <i>Viruses</i> , 2019, 11, 263.	3.3	1
180	Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection-â€”Pilot study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 400-409.	2.0	1

#	ARTICLE	IF	CITATIONS
181	Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2021, 99, 491-498.	1.9	1
182	Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib. <i>Internal Medicine</i> , 2021, 60, 2047-2053.	0.7	1
183	Are Humanized Mouse Models Useful for Basic Research of Hepatocarcinogenesis through Chronic Hepatitis B Virus Infection?. <i>Viruses</i> , 2021, 13, 1920.	3.3	1
184	Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL. <i>Journal of Infectious Diseases</i> , 2023, 227, 686-695.	4.0	1
185	Multicentric hepatocarcinogenesis at 6 and 13 years after sustained viral response to hepatitis C virus. <i>Clinical Journal of Gastroenterology</i> , 2012, 5, 204-209.	0.8	0
186	Reply from the authors. <i>Hepatology Research</i> , 2020, 50, 1393-1393.	3.4	0
187	A case of simultaneous hepatocellular carcinoma and cholangiocellular carcinoma in a patient with alcoholic liver injury. <i>Acta Hepatologica Japonica</i> , 2021, 62, 300-309.	0.1	0
188	Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice. <i>Biochemical and Biophysical Research Communications</i> , 2021, 559, 78-83.	2.1	0